Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-096252
Filing Date
2024-11-12
Accepted
2024-11-12 08:10:41
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0219261-10q_protara.htm   iXBRL 10-Q 740841
2 CERTIFICATION ea021926101ex31-1_protara.htm EX-31.1 13157
3 CERTIFICATION ea021926101ex31-2_protara.htm EX-31.2 13014
4 CERTIFICATION ea021926101ex32-1_protara.htm EX-32.1 7171
  Complete submission text file 0001213900-24-096252.txt   4751493

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tara-20240930.xsd EX-101.SCH 51745
6 XBRL CALCULATION FILE tara-20240930_cal.xml EX-101.CAL 38576
7 XBRL DEFINITION FILE tara-20240930_def.xml EX-101.DEF 211539
8 XBRL LABEL FILE tara-20240930_lab.xml EX-101.LAB 410261
9 XBRL PRESENTATION FILE tara-20240930_pre.xml EX-101.PRE 220273
72 EXTRACTED XBRL INSTANCE DOCUMENT ea0219261-10q_protara_htm.xml XML 552099
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 241443609
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)